EXELExelixis, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap vs its sector.
Priced for a decline (~−2% a year). The price demands less than its three-year revenue growth of 12% a year, expectations look modest.
In its normal range: P/E 18.8 vs a 24.6 median over 37 quarters (−24% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What EXEL's price assumes
Exelixis, Inc. trades at 18.8× earnings against 18.8× for the median Biotechnology name, cheaper than its own group.
Trailing P/E · Biotechnology median 18.8 · cheaper than the typical name in its group
- Price / sales
- 5.77
Price / sales · today's price, fiscal year to Jan 2, 2026
- Free cash flow yield
- 8.8%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- −1.8%
Growth the price implies · The price pays for −1.8% free cash flow growth a year for a decade; the business has delivered +49% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Jan 2, 2026
- 6.19
- EV / EBITtoday's price, fiscal year to Jan 2, 2026
- 14.1
- EV / salestoday's price, fiscal year to Jan 2, 2026
- 5.31
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $1.17B
- Market capitalisation
- $13.4B
- 3-year revenue growth
- +12%
- 3-year free cash flow growth
- +49%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $52.92 |
| Its own P/E history, median | $78.27 |
| Its own P/E history, upper quartile | $128.59 |
| 52-week range | $34.54 – $59.86 |
| Today | $59.86 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.